Dosing of antimicrobial agents in critically-ill patients with acute kindey injury and continuous venvenous haemofiltration

Acta Clinica Belgica

Volumn 62, Issue SUPPL. 2, 2007, Pages 365-370

  Bouman, Catherine S C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antibiotics; Continuous venovenous haemofiltration; Pharmacokinetics; Sieving coefficient

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CEFTAZIDIME; FLUCONAZOLE; LEVOFLOXACIN; MEROPENEM;

ACUTE KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; PRACTICE GUIDELINE; TISSUE PERFUSION; TREATMENT RESPONSE; BLOOD; COMPARATIVE STUDY; CRITICAL ILLNESS; INTENSIVE CARE UNIT; METHODOLOGY; REVIEW; TIME;

ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; HEMOFILTRATION; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE, ACUTE; TIME FACTORS;

EID: 41149088846     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.082     Document Type: Conference Paper

References (28)

1. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30: 2145-56.
2. Subach RA, Marx MA. Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics. Adv Ren Replace Ther 1998; 5: 141-7.
3. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-8.
4. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: A worldwide practice survey :The Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Med 2007; 33; 1563-70.
5. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45: 929-34.
6. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362-79.
7. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21: 612-20.
8. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30.
9. Benet LZ, Williams RL. Design and optimization of dosage regimens: pharmacokinetic data. In: Goodman Gilman A, Rall TW Nies AS Taylor P.(eds) The pharmacological basis of therapeutics. Mc Graw-Hill International New York, 1650-735.
10. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3: 155-93.
11. Bohler J, Donauer,J, Keller,F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999; 72: S24-S8.
12. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42: 2417-20.
13. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985; 8: 307-12.
14. Lam YW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 30-57.
15. Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis 1986; 8: 7-17.
16. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999; 56: 2005-15.
17. Lau AH, Kronfol NO. Determinants of drug removal by continuous hemofiltration. Int J Artif Organs 1994; 17: 373-8.
18. Bouman CS, van Kan HJ, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32: 2013-9.
19. Joos B, Schmidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996; 11: 1582-5.
20. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28: 632-7.
21. Guenter SG, Iven H, Boos C, Bruch HP, Muhl E. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 2002; 22: 175-83.
22. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003; 49: 280-6.
23. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45: 3148-55.
24. Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-8.
25. Traunmuller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002;49:129-34.
26. Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000; 28: 3412-6.
27. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 1999; 25: 1100-4.
28. Matzke GR, O'Connell MB, Collins AJ, Keshaviah PR. Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 1986; 40: 425-30.